Michael Schlander

from Wikipedia, the free encyclopedia

Michael Schlander (* 1959 in Offenbach am Main ) is a German doctor and economist . He is Professor of Health Economics at the University of Heidelberg and heads the Division for Health Economics at the German Cancer Research Center (DKFZ) in Heidelberg.

Life

Schlander studied human medicine and psychology at the University of Frankfurt , where he worked as a scientific assistant in neuroanatomy and (after his license to practice medicine in 1985) in neurology . In 1987 he did his doctorate under Michael Frotscher with a combined light and electron microscopic study of interneurons ("non-pyramidal cells") in the hippocampus, which was awarded the title summa cum laude . He completed his studies in economics at the University of Seattle / Washington as the best of his year (Valedictorian of the class of 1994). He also studied health economics at the Stockholm School of Economics and received the Venia legendi for this subject from the Ruprecht-Karls-Universität Heidelberg . He was co-founder of a postgraduate course in Pharmaceutical Medicine at the University of Witten / Herdecke and from 1996 to 2005 a member of the medical faculty of this university; from 2005 to 2008 in the same function at the University of Duisburg-Essen in Essen , where he taught health economics and innovation management . Since 2006, Schlander has been involved in developing a master’s degree in health economics at the Mannheim Institute for Public Health, Social and Preventive Medicine at Heidelberg University. Also since 2006, his institute has been organizing a summer academy for health economics, which has been taking place in Heidelberg since 2007 and is internationally recognized. The Heidelberg Health Economics Summer School, which he inaugurated, has been taking place since 2019 under the auspices of Heidelberg University and the German Cancer Research Center (DKFZ).

From 1987 to 2002 Schlander held management positions in the pharmaceutical industry in the functional areas of clinical research , marketing and management in Germany, Belgium and the USA a. a. worked for Sandoz ( Novartis since 1996 after the merger with Ciba-Geigy ), Byk Gulden and Johnson & Johnson . From 1993 to 1998 Schlander was responsible for the development of a strategic business unit of the Byk Gulden company (later Altana Pharma, then Nycomed , in 2011 taken over by Takeda , the largest Japanese pharmaceutical manufacturer) with headquarters in Konstanz on Lake Constance. There he managed, among other things, one of the most successful new product launches in the German pharmaceutical industry, the German and international marketing and further development of pantoprazole , a proton pump inhibitor (PPI) for the treatment of gastric acid-associated diseases.

From 2002 to 2016, Schlander held a professorship for (health and innovation) management at the Ludwigshafen University of Economics . In June 2005 he founded the Institute for Innovation & Evaluation in Healthcare, which is recognized as a non-profit organization and is based in Wiesbaden. His work focuses on the areas of health economics and innovation management . Schlander was one of the co-founders of the German Society for Health Economics ( dggö ) and was the scientific director of a project that resulted in a consensus among health insurers (santésuisse), the Swiss medical community ( FMH ) and the research-based pharmaceutical industry ( Interpharma ) on the systematic application of Health Technology Assessment including economic evaluations in the Swiss healthcare system. He also studies the health economics of attention deficit hyperactivity disorder (ADHD). In 2012, Schlander was one of the two scientific directors of the 15th European Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Berlin.

At the German Cancer Research Center (DKFZ), he has been building up a new department for health economics since 2017, whose work focuses on the areas of cost of illness analysis, cost-benefit analysis and the further development of conventional health economic evaluation methodology. Special attention is paid to the psychosocial consequences of illness from the perspective of the affected patients and their families, as well as the inclusion of the “social preferences” of citizens in the prioritization of health services within the framework of health systems organized in solidarity.

Publications

  • Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE): A Qualitative Study . Springer, New York: 2007.
  • The Contribution of Health Economics to Market-Oriented Pharmaceutical Research and Development . University of Witten / Herdecke Verlagsgesellschaft, Witten: 1998.

Individual evidence

  1. ↑ https://indico.dkfz.de/event/81/
  2. ↑ Institute for Innovation & Evaluation in Health Care (InnoVal-HC)
  3. ↑ ISPOR 15th Annual European Congress (Berlin 2012) ( Memento from January 31, 2012 in the Internet Archive )
  4. ↑ https://www.dkfz.de/de/gesundheitsoekonomie/index.php

Web links

personal data
SURNAME Schlander, Michael
BRIEF DESCRIPTION German doctor and economist
DATE OF BIRTH 1959
PLACE OF BIRTH Offenbach am Main